Heart failure & cardiomyopathiesCohort study
Identifying Predictors for Heart Failure Outcomes in Phospholamban p.(Arg14del)–Positive Individuals
- Registry-based cohort study
Authors' conclusion
This study identified predictors for heart failure outcomes in PLN p.(Arg14del)-positive individuals that can improve risk prediction.
Study context
- Population
- Phospholamban (PLN) p.(Arg14del)-positive individuals, PLN/ACM Registry
- Participants
- 904 participants
- Outcome
- Composite of HF outcomes (HF hospitalization, LV or biventricular assist device implantation, heart transplantation, or HF-related death)
- Follow-up
- Median 5.4 years
Main finding
As reported in the abstract
Composite HF outcomes · median follow-up 5.4 years (Q1-Q3: 2.3-9.7 years)
- Participants reaching the primary endpoint
- 116 (13%)
- HF hospitalization (share of primary endpoint)
- 75%
- Heart transplantation (share of primary endpoint)
- 10.3%
- LV or biventricular assist device implantation (share of primary endpoint)
- 9.5%
- HF-related death (share of primary endpoint)
- 5.2%
Observational data: associations, not effects.
Original publication
Identifying Predictors for Heart Failure Outcomes in Phospholamban p.(Arg14del)–Positive Individuals. JACC Heart Fail. Published 9 August 2025. doi:10.1016/j.jchf.2025.102558
Summarised from the published abstract; every number is checked against it